All In Biotech

Drug Trial Radar · NCT05110261

Evaluate the Safety and Efficacy of Nirsevimab in Healthy Preterm and Term Infants in China

A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Nirsevimab, a Monoclonal Antibody With Extended Half-life Against Respiratory Syncytial Virus, in Healthy Preterm and Term Infants in China

Last checked: Nov 20, 2026Latest source record: Oct 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 800 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

800

Actual

Start

Nov 24, 2021

Primary completion

Nov 24, 2025

Study completion Nov 24, 2025

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
Collaborators
IQVIA RDS Inc.
First posted
Nov 5, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 0 years, up to 1 year
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the Safety and Efficacy of Nirsevimab, in Healthy Preterm and Term Infants in China

Conditions

  • Lower Respiratory Tract Infection

Interventions

  • NirsevimabDrug

    Drug: injection, 100 mg/mL, a single fixed IM dose of 50 mg (if weight \< 5 kg) or 100 mg (if weight ≥ 5 kg)on day 1 only.

  • PlaceboDrug

    Commercially available 0.9% (w/v) saline (sterile for human use) fixed IM dose of 0.5 mL (if weight \<5 kg) or 1.0 mL (if weight \>=5 kg)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of medically attended LRTI due to RT-PCR-confirmed RSVTime frame: Day 1 to Day 151

Locations

30 sites in 1 country. Site status is shown where the registry gives one.

  • Research Site

    Beijing, China

  • Research Site

    Changde, China

  • Research Site

    Changsha, China

  • Research Site

    Changsha, China

  • Research Site

    Chengdu, China

  • Research Site

    Chengdu, China

  • Research Site

    Guangzhou, China

  • Research Site

    Guangzhou, China

  • Research Site

    Guangzhou, China

  • Research Site

    Hangzhou, China

  • Research Site

    Hangzhou, China

  • Research Site

    Jiaxing, China

  • Research Site

    Kunming, China

  • Research Site

    Langfang, China

  • Research Site

    Linfen, China

  • Research Site

    Linfen, China

  • Research Site

    Nanjing, China

  • Research Site

    Ningbo, China

  • Research Site

    Sanmenxia, China

  • Research Site

    Sanya, China

  • Research Site

    Shantou, China

  • Research Site

    Shaoxing, China

  • Research Site

    Shenzhen, China

  • Research Site

    Suzhou, China

  • Research Site

    Tangshan, China

  • Research Site

    Tianjin, China

  • Research Site

    Wenzhou, China

  • Research Site

    Xinxiang, China

  • Research Site

    Zhengzhou, China

  • Research Site

    Zhongshan, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.